Research programme: anxiety and depression therapeutics - Evotec AG
Latest Information Update: 14 Jan 2010
At a glance
- Originator Evotec AG
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Anxiety disorders; Major depressive disorder
Most Recent Events
- 29 Mar 2007 Neuro3d has been acquired and merged into Evotec AG
- 06 Apr 2004 Preclinical trials in Depression in France (unspecified route)
- 06 Apr 2004 Preclinical trials in Anxiety disorders in France (unspecified route)